NCT03787745 Ischemic Postconditioning in STEMI Patients Treated With Primary PCI
| NCT ID | NCT03787745 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rigshospitalet, Denmark |
| Condition | ST Segment Elevation Myocardial Infarction |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,800 participants |
| Start Date | 2019-02-04 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,800 participants in total. It began in 2019-02-04 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In a prospective, randomized clinical trial the iPOST2 trial will determine whether ischemic postconditioning reduces reperfusion injury and this will translate into improved clinical outcome of heart failure and death for STEMI patients who present with TIMI0-1 undergoing primary PCI
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Acute onset of chest pain with \< 12 hours duration * STEMI as characterized by 2 mm ST elevation in 2 or more V1 through V4 leads or presumed new left bundle branch block with minimum of 1 mm concordant ST elevation or 1 mV ST-segment elevation in the limb lead (II, III and aVF, I, aVL) and V4-V6 or ST depression in 2 or more V1 through V4 leads indicating posterior AMI. * TIMI flow 0-1 in infarct related artery Exclusion Criteria: * Potential pregnancy * Refusal to participate * OHCA without subsequent consciousness despite ROSC * Thrombectomy considered unavoidable
Contact & Investigator
Thomas Engstrøm, DMSci
STUDY CHAIR
Rigshospitalet, Denmark
Frequently Asked Questions
Who can join the NCT03787745 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying ST Segment Elevation Myocardial Infarction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03787745 currently recruiting?
Yes, NCT03787745 is actively recruiting participants. Contact the research team at thomas.engstroem@regionh.dk for enrollment information.
Where is the NCT03787745 trial being conducted?
This trial is being conducted at Copenhagen, Denmark.
Who is sponsoring the NCT03787745 clinical trial?
NCT03787745 is sponsored by Rigshospitalet, Denmark. The principal investigator is Thomas Engstrøm, DMSci at Rigshospitalet, Denmark. The trial plans to enroll 1,800 participants.